BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas (PNOC017)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03749187

Recruitment Status : Recruiting

First Posted : November 21, 2018

Last Update Posted : February 23, 2024

See Contacts and Locations

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborators:

BeiGene USA, Inc.

Pacific Pediatric Neuro-Oncology Consortium

Information provided by (Responsible Party):

Sabine Mueller, MD, PhD, University of California, San Francisco

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Recruiting
Estimated Primary Completion Date :	June 30, 2024
Estimated Study Completion Date :	July 30, 2029

To Top